RadNet, Inc. - RDNT STOCK NEWS

RadNet, Inc. (NASDAQ: RDNT) has initiated its Enhanced Breast Cancer Detection (EBCD) service, designed to improve breast cancer screening accuracy in New York and New Jersey. This service incorporates the Saige-Dx™ AI technology, an advanced tool for analyzing mammograms, alongside personalized lifetime risk assessments and a dedicated support line. EBCD aims to empower patients by offering more informative mammograms and addressing their concerns regarding breast cancer risk. The service is supported by extensive AI training on over one million images, enhancing radiologists’ efficiency and accuracy. RadNet continues to lead in AI-driven radiology solutions.

On February 6, 2023, RadNet (NASDAQ: RDNT) announced the launch of its Enhanced Breast Cancer Detection (EBCD) service. This innovative service integrates advanced AI technologies, including Saige-Dx™, to provide patients with enhanced mammography accuracy and personalized lifetime risk assessments for breast cancer. The program aims to improve early detection through AI-driven analysis and includes a support line for patient inquiries. According to company executives, the EBCD service enhances the quality of breast cancer screenings, ultimately aiming to improve patient outcomes.

RadNet announced that its subsidiary, DeepHealth, received FDA clearance for its AI mammography density assessment tool, Saige-Density™. This innovative software automates breast density categorization, aiding radiologists in detecting cancer more effectively. With nearly half of women over 40 classified as having dense breast tissue, this tool is crucial for accurate evaluations, especially as many states mandate breast density notifications. Saige-Density™ is the third AI product from DeepHealth to gain FDA approval, showcasing the company's commitment to enhancing mammography through advanced technology.

RadNet, a leader in diagnostic imaging services, announced that Chief Financial Officer Mark Stolper will present at the Sidoti & Company December 2022 Small-Cap Virtual Conference. The presentation is scheduled for December 7, 2022, at 3:15 PM Eastern Time. Attendees can access the live and archived webcasts on RadNet's website under the 'About RadNet' section and on the Sidoti platform. RadNet operates 349 outpatient imaging centers across several states, employing about 9,000 individuals.

Delaware Imaging Network, part of RadNet (NASDAQ: RDNT), has launched the Enhanced Breast Cancer Detection (EBCD) service to improve mammography accuracy. This new service uses advanced AI technologies, including Saige-Dx™, to assist in breast cancer screenings. Key features include AI-driven reviews, comprehensive risk assessments, and a dedicated support line. This initiative aims to empower women with better health information and potentially improve patient outcomes. Dr. Berger emphasized EBCD as a significant advancement in patient care, positioning RadNet at the forefront of radiology innovation.

RadNet, Inc. (NASDAQ: RDNT) announced a partnership between its AI subsidiary Aidence and Google Health to license AI technology for lung nodule malignancy prediction. This collaboration aims to enhance early lung cancer diagnosis and minimize unnecessary procedures. Lung cancer screenings with low-dose CT significantly reduce mortality rates. Aidence's deep learning model will be developed and validated with Google Health's expertise, although no regulatory applications or sales orders have been initiated yet. The partnership focuses on improving clinical workflows and deployment of AI in diagnostics.

RadNet, Inc. (NASDAQ: RDNT) will have its Executive Vice President and Chief Financial Officer, Mark Stolper, present at the BofA Securities 2022 Leveraged Finance Conference on November 29, 2022, at 11:50 a.m. PT. The presentation will take place in Boca Raton, FL. Interested parties can access live and archived webcasts through BofA's website and RadNet's official site under the “About RadNet” section.

RadNet, NASDAQ: RDNT, reported a 5.2% revenue increase to $350 million in Q3 2022, driven by its Imaging Centers segment, which grew 5.1% to $349.1 million. However, Adjusted EBITDA fell 8.5% to $50.2 million, primarily due to rising costs and labor shortages. Net Income dropped to $668,000 with diluted earnings per share at $0.01. The company revised its full-year guidance downward, citing ongoing cost challenges. Future growth strategies include operational expansions and acquisitions to enhance service capacity.

RadNet, Inc. (NASDAQ: RDNT) has acquired a 75% interest in London-based Heart & Lung Imaging Limited, enhancing its capacity in lung cancer diagnostics. HLH operates a network of over 70 radiologists and is a leader in NHS England's Targeted Lung Health Check (TLHC) program, which aims to screen one million lung cancer patients by 2026. This acquisition leverages RadNet’s AI technology to improve diagnostic accuracy and reduce mortality rates in lung cancer. CEO Dr. Howard Berger emphasized the strategic importance of early detection in improving patient outcomes and reducing healthcare costs.